The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study

Table 5 Correlation between improvements (%) in lower urinary tract symptoms & female sexual function

	Desire		Arousal		Lubrication		Orgasm		Satisfaction		Pain		Total FSFI
	r_s	P	r_s	P	r_s	P	r_s	P	r_s	P	r_s	P	r_s	P
Group A
Frequency	−0.088	0.553	0.220	0.298	− 0.201	0.171	− 0.237	0.104	0.015	0.918	− 0.105	0.479	− 0.254	0.081
Urgency	0.168	0.253	0.041	0.781	−0.195	0.199	−0.240	0.135	0.035	0.815	0.013	0.928	−0.224	0.127
Nocturia	0.209	0.154	0.157	0.286	−0.188	0.201	0.062	0.674	0.240	0.101	−0.054	0.714	0.181	0.219
Incontinence	−0.007	0.960	0.158	0.283	0.134	0.364	−0.270	0.064	0.101	0.496	−0.076	0.610	−0.026	0.858
Pads	−0.114	0.442	−0.076	0.607	−0.076	0.609	−0.180	0.114	0.119	0.422	−0.128	0.384	−0.222	0.150
Voided Volume	0.041	0.782	−0.067	0.651	−0.114	0.441	−0.010	0.948	0.228	0.119	0.126	0.393	0.077	0.603
Group B
Frequency	0.103	0.545	−0.284	0.089	−0.429	0.008	0.139	0.413	−0.037	0.826	−0.230	0.170	−0.267	0.110
Urgency	0.005	0.977	−0.002	0.991	0.163	0.335	−0.119	0.484	0.253	0.132	0.011	0.946	0.008	0.638
Nocturia	−0.041	0.808	−0.352	0.032	−0.145	0.391	−0.062	0.716	0.161	0.340	0.080	0.640	−0.056	0.743
Incontinence	0.178	0.292	−0.336	0.042	−0.009	0.957	−0.209	0.214	0.250	0.130	0.206	0.221	0.068	0.687
Pads	0.123	0.468	−0.253	0.131	0.068	0.689	0.125	0.461	0.298	0.073	0.202	0.230	0.156	0.357
Voided Volume	0.186	0.271	−0.170	0.314	−0.074	0.663	0.269	0.108	0.205	0.223	0.161	0.340	0.177	0.294

ISSN: 1471-2490